Table 5 Multivariate Cox proportional hazards analysis for PFS and OS used to adjust risk associated prognostic clinical features
From: Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study
Pure group (n = 164) | PFS | OS | ||
| Â | HR (95%CI) | p-value | HR (95%CI) | p-value |
Parity | 0.906 (0.508–1.615) | 0.738 | / | / |
CA-125(before) | 1.000 (0.999–1.000) | 0.595 | 1.646 (0.403–6.725) | 0.487 |
CA-125(after) | 1.002 (1.000–1.005) | 0.044 | / | / |
FIGO | 1.722 (0.990–2.994) | 0.054 | 3.981 (1.821–8.706) | 0.001 |
EM-related | 4.014 (1.056–15.262) | 0.041 | 0.925 (0.272–3.146) | 0.047 |
Residual disease | 0.915 (0.475–1.766) | 0.792 | 1.389 (0.823–2.346) | 0.219 |
Lymph Nodes excision | 0.325 (0.078–1.346) | 0.325 | 0.925 (0.272–3.146) | 0.900 |
Mixed group (n = 47) | PFS | OS | ||
| Â | HR (95%CI) | p-value | HR (95%CI) | p-value |
CA-125(before) | 1.000 (0.999–1.001) | 0.835 | 1.000 (1.000–1.001) | 0.185 |
CA-125(after) | 1.003 (0.998–1.008) | 0.235 | / | / |
FIGO | 1.934 (0.211–17.700) | 0.023 | 1.880 (0.699–5.059) | 0.211 |
EM-related | / | / | / | / |
Residual disease | 1.490 (0.544–4.087) | 0.544 | 1.030 (0.508–2.086) | 0.935 |
Mixed with EC | 0.070 (0.014–0.347) | 0.001 | 0.425 (0.107–1.684) | 0.223 |
Appendix excision | 4.460 (0.350–56.794) | 0.249 | 0.228 (0.041–1.258) | 0.090 |
Lymph Nodes excision | 1.934 (0.211–17.700) | 0.559 | 1.030 (0.508–2.086) | 0.935 |
2–4 stage of patients with pure cancer | PFS | |||
HR (95%CI) | p-value | |||
FIGO | 2.918 (1.022–8.326) | 0.045 | ||
R0 | 0.287 (0.110–0.749) | 0.011 | ||